Advertisement

Reactions Weekly

, Volume 1731, Issue 1, pp 226–227 | Cite as

Programmed-cell-death-1-receptor-antagonists/proto-oncogene-protein-b-raf-inhibitors/mitogen-activated-protein-kinase-kinase-inhibitors

Various toxicities: 11 case reports
Case report
  • 18 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a retrospective chart review, 5 women and 6 men aged 28−82 years were described, who developed rash, a diffuse erythematous reaction, facial swelling, ocular irritation, whole body rash, nausea, vomiting, fever, pneumonitis, liver enzyme elevation, poor appetite, chills, diarrhoea, weakness, cytokine release syndrome, arthralgia or hypotension during treatment with vemurafenib, dabrafenib, cobimetinib, trametinib, pembrolizumab, ipilimumab or nivolumab [not all routes, dosages and outcomes stated].

Patient 1: A 48-year-old man with BRAFV600E-positive metastatic melanoma was treated with pembrolizumab, but melanoma progressed after the four cycles of pembrolizumab. Thereafter, he received pembrolizumab along with CMP-001. The melanoma again progressed after four cycles....

Reference

  1. Grogan N, et al. Toxicities with targeted therapies after immunotherapy in metastatic melanoma. Melanoma Research 28: 600-604, No. 6, Dec 2018. Available from: URL: http://doi.org/10.1097/CMR.0000000000000493 -USACrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations